Many in v'ivo studies have been carried out on purine metabolism in man because of the presence of a readily available end product, uric acid. In the absence of a comparable unique end product, no previous over-all measurements of pyrimidine metabolism in the intact organism have been reported. Studies have been limited to the excretion of /8-aminoisobutyric acid, as a metabolite of thymine (1), the incorporation of pyrimidine precursors into circulating leukocytes (2), the induced urinary excretion of orotic acid and orotidine (3), and the spontaneous urinary excretion of certain trace pyrimidines (4). In this report a method is described for evaluating pyrimidine nucleotide synthesis in the intact organism, based on the release of carbon dioxide-C14 from carboxyl-labeled pyrimidine precursors. The usefulness of this procedure in defining the onset, degree, and duration of action of certain antimetabolites is illustrated by studies in rats, and in patients with leukemia.
Many in v'ivo studies have been carried out on purine metabolism in man because of the presence of a readily available end product, uric acid. In the absence of a comparable unique end product, no previous over-all measurements of pyrimidine metabolism in the intact organism have been reported. Studies have been limited to the excretion of /8-aminoisobutyric acid, as a metabolite of thymine (1) , the incorporation of pyrimidine precursors into circulating leukocytes (2) , the induced urinary excretion of orotic acid and orotidine (3) , and the spontaneous urinary excretion of certain trace pyrimidines (4) . In this report a method is described for evaluating pyrimidine nucleotide synthesis in the intact organism, based on the release of carbon dioxide-C14 from carboxyl-labeled pyrimidine precursors. The usefulness of this procedure in defining the onset, degree, and duration of action of certain antimetabolites is illustrated by studies in rats, and in patients with leukemia.
MATERIALS AND METHODS
Intravenous injections of labeled compounds were given through indwelling jugular vein catheters to male albino rats, weighing 125 to 150 g. For collection of expired C1402, air was flushed through a closed metabolic chamber and the carbon dioxide trapped in 3 N NaOH. Acidification of aliquots of this solution allowed trapping of the carbon dioxide in Hyamine base and counting in a Packard Tri-Carb liquid scintillation spectrometer at an efficiency of approximately 45 40 per cent. Orotic acid in the urine was identified by ascending paper chromatography in a propanol: HO: formic acid system (7: 2:1) through comparison with known standard (Rf approximately 0.40) and also from ultraviolet spectrophotometry of acid solutions of the eluted spots (5) .
In human subjects, after intravenous injection of labeled compounds, expired air was collected in meteorological balloons. Measured aliquots were passed through 3 N NaOH, which was treated as in the rat assays.
Orotic acid-C1' (OA-C4), labeled in either the C-6 or C-7 (carboxyl) position, was purchased from the New England Nuclear Corporation. D,L-Carbamylaspartic acid-C1 (CAA-C"4), labeled in the ureide position, was synthesized as previously described (5) . D,L-CAA-C14, labeled in the C-1 position (corresponding to the carboxyl carbon of orotic acid), was synthesized by alkaline hydrolysis of carboxyl-labeled dihydroorotic acid-C1' (5) . Specific activity as utilized was approximately 0.2 /Ac per jsmole.
Other compounds used in these studies were gifts from the following sources: potassium oxonate, Dr. Robert E. Handschumacher; 6-azauridine, Dr. Emil Frei, III; 5-fluoroorotic acid and azaserine, Dr. Thomas C. Hall; imidazoleacetic acid hydrochloride, Dr. Howard H. Hiatt; 6-azauracil, Wellcome Research Laboratories; 2-ethylamino-1,3,4-thiadiazole, Lederle Laboratories Division of American Cyanamid Co.; Colcemide, Ciba Pharmaceutical Products, Inc. 6-Mercaptopurine was purchased from Nutritional Biochemicals Corp.
RESULTS
Validation of the method. In the biosynthetic sequence of pyrimidine nucleotide formation, an irreversible decarboxylation occurs in the conversion of orotidine-5'-phosphate (05P) to uridine-5'-phosphate (UMP) (Figure 1 ). In a partially purified system of orotidylic pyrophosphorylase and orotidylic decarboxylase from yeast, the release of C1402 from carboxyl-labeled orotic acid has been shown to be a reliable measure in vitro of pyrimidine nucleotide formation (6) . No index of pyrimidine biosynthesis, at least three postulates must be confirmed by experimental data: 1) C'402 should be released more rapidly from precursors when the label is in the carbon atom destined to become the carboxyl group of 05P than when the isotopic carbon is elsewhere in the molecule; 2) antimetabolites whose action has been demonstrated in vitro to inhibit UMP synthesis should interfere with the respiratory excretion of C1402 from carboxyl-labeled precursors given in vivo; 3) antimetabolites whose action is not directed toward pyrimidine biosynthesis should not "nonspecifically" interfere with the metabolism of the test compounds.
1) Degradative enzymatic systems have been described in mammalian preparations which release CO2 from pyrimidine precursors without prior formation of pyrimidine nucleotides (7, 8 Figure 1 ). In Figure 2 , a comparison is presented of the rates at which the rat expired C1402 after the intravenous injection of 1.67 Mmoles per 100 g body weight of carboxyl-labeled or C-6-labeled orotic acid (OA-C14). Approximately 50 per cent of the isotope administered as carboxyl-labeled OA-C'4 appeared in the expired air in 1 hour; another 37 per cent was excreted in the urine. Intravenous injection of C-6-labeled OA-C14 resulted in the respiratory recovery of less than 3 per cent of the administered radioactivity within 1 hour, but the excretion of similar amounts (32 per cent) in the urine (Table I) . Chromatographic studies revealed the urinary radioactivity to be that of unaltered orotic acid. The first compound unique to pyrimidine biosynthesis is carbamylaspartic acid (CAA), which is converted by four enzymatic steps to UMP with loss of its 1-carboxyl group as CO, ( Figure   1 range utilized, the catabolic degradation of the administered precursors was negligible.
2) The locus of action of a number of antineoplastic agents has been determined at an enzymatic level using well defined in vitro preparations. An antimetabolite, whose action has been elucidated by such studies to be inhibition of UMP synthesis, should interfere with the respiratory output of C1402 from carboxyl-labeled precursors, as determined in the assay here employed. Three such antimetabolites were chosen to test this postulate-6-azauracil or its riboside, 6-azauridine, 5-fluoroorotic acid, and oxonic acid ( Figure 4 ).
Extensive evidence has been presented that 6-azauracil and 6-azauridine are converted enzymatically to 6-azauridylic acid (6AUMP) (9) , which serves as a highly specific competitive inhibitor of orotidylic decarboxylase (10) . The accumulation of orotidine in liver and tumors of rats (11) and the induction of orotic aciduria and orotidinuria in rats (12) and in man (3) after administration of 6-azauridine lend added support for the in vivo specificity of this inhibition, which blocks the conversion of orotidine-5'-phosphate to uridine-5'-phosphate. Preliminary studies with 6-azauracil administered intraperitoneally to rats (440 umoles per 1000 g body weight) showed marked inhibition of C1402 recovery from carboxyl-labeled OA-C14 ( Figure 5 ). The intraperitoneal injection of 6-azauridine (75 Mmoles per 100 g body weight) led to an 80 per cent reduction in expired radioactivity, with a simultaneous 60 per cent increase in the radioactivity recovered in the urine over the 1 hour test period ( Figure 6 ). Since diminished C1402 evolution could be secondary to a loss of available substrate through increased renal excretion of orotic acid, a similar study with 6-azauridine pretreatment was carried out on cumulative total of respiratory output of radioactivity. 5-Fluoroorotic acid is an inhibitor at a number of steps in pyrimidine nucleotide and nucleic acid biosynthesis. These include inhibition of the 5-methylation reaction in the formation of thymidylic acid (13) , feedback inhibition of earlier stages of pvrimidine synthesis (14) , and incorporation into "fraudulent" nucleic acids (15) . In vitro studies have demonstrated that, as an orotic acid analogue, it also competitively inhibits the conversion of OA to 05P by orotidylic pyrophosphorylase (enzyme 4, Figure 1 OA-C14 or 1-carboxyl-labeled CAA-C14 administration to the rat, similar effects should be found with analogous antimetabolites whose primary action is on purine synthetic pathways. As in the case of 5-fluoroorotic acid, 6-mercaptopurine exhibits a diversity of actions, which include feedback inhibition of earlier stages of purine biosynthesis (19) , and interference with the conversion of inosine-5'-phosphate to other purine nucleotides (20) . The (24) , exhibits a unique property of increasing uric acid synthesis in man unrelated to tissue destruction (25) . Although the precise mechanism of its action has yet to be defined, indirect evidence suggests that it may participate as a nicotinamide analogue (26) . Intraperitoneal injection of 2-ethylamino-1,3,4-thiadiazole in the maximum daily dose tolerated by the rat (25 mg per 100 g) (24), did not affect the decarboxylation of carboxyl-labeled OA-C14 administered 30 minutes later. Similarly, colchicine, administered intravenously as an LD20 dose of Colcemide (2 mg per 100 g) (27) , was without effect on the rate of C140, recovery in the test system. In summary, antineoplastic agents whose sites of action are not in the pyrimidine biosynthetic sequence failed to inhibit significantly the release of C140, from carboxyl-labeled pvrimidine precursors.
Variables in the assay systemt. There are a number of variables inherent in this in vivo test system. Evidence concerning the site of metabolism of orotic acid in the rat was obtained by removal of two-thirds of the liver and by eviscerectomy with functional hepatectomy (28) . These manipulations diminished C140, excretion by 60 and 85 per cent, respectively, suggesting that the liver is by far the major site of pyrimidine nucleotide synthesis from exogenous precursors ( Figure  8 ). Since a third of the administered OA-C14 was lost in the urine within 30 minutes in the control rats, changes in renal function might be expected to affect the C140, recovery by altering substrate availability. Although total recovery of C1409 was elevated 1 hour after injection of carboxyl-labeled OA-C14 to an acutely nephrectomized rat, the initial rate over the first 30 minutes was not appreciably altered (Table II) . In addition, while acute nephrectomy does not serve as a fully suitable control for the hepatec- The effect of increasing doses of administered carboxyl-labeled OA-C14 was studied to determine whether saturation of a limiting factor in orotic acid metabolism in the rat (transfer across cell membranes, enzyme concentration per se, availability of cofactors, and so forth) had been attained, or whether the administered isotope served merely to label the endogenous pool of the corresponding precursor. The recovery of C1402 over the 30 minute test period was proportionate to the injected dose of carboxyl-labeled OA-C14 within the dose range studied ( Figure 9 ). It was concluded that the dose of orotic acid most frequently used in the rat ( Oover 30 minutes after intravenous ad-100 mose I cAA per 100 g) suggested that the n to the rat of varying doses of carboxyl-test dose of orotic acid administered in these extic acid-C". The ordinate is plotted as cpm periments (1.67 Emoles per 100 g) should put no in expired CO,/specific activity of OA-C" great demand on the availability of PRPP (34 (Figure 10 ).
Onset and duration of antimetabolite effect. As an index of in vivo pyrimidine nucleotide biosynthesis, the recovery of respiratory C1402 after administration of carboxyl-labeled pyrimidine precursors should allow information to be obtained concerning several aspects of the pharmacology of antineoplastic agents-the rapidity of action, the degree of inhibition, and the duration of the biochemical effectiveness. The degree of inhibition obtained has been illustrated above in the rat (Figures 5-7 ) and in man (Figure 10 ). The rapidity of onset of action of 6-azauridine in man was studied in two instances, one of which is illustrated in Figure 11 . A constant infusion of carboxyllabeled OA-C14 was administered throughout the experimental period to J.G., a 69 year old man with chronic lymphocytic leukemia. When equilibrium of C1402 evolution was approached, 90 minutes after the start of the constant infusion, 6-azauridine (60 mg per kg) was rapidly injected intravenously. Diminution in respiratory C'402 excretion was noted within the first 10-minute collection period. It between the release of C1409 from carboxyl-labeled orotidine-5'-phosphate and its recovery in the expired air, tends to obscure this measurement of rapidity of action. The extent of inhibition cannot be documented in this instance, because of a presumed increase in blood and tissue levels of orotic acid after administration of the antimetabolite.
More precise information was obtained in the series of experiments on rats summarized in Figure 12 . Rats received test injections of carboxyllabeled orotic acid-C14 at varying intervals of time after an intravenously administered "therapeutic dose" of 6-azauridine (10 umoles per 100 g) (9) . Each point represents the rate of C1402 evolution in an individual rat pretreated with 6-azauridine compared with its own previous control performance. The points for individual experiments are spread on an abscissa representing the time interval between 6-azauridine administration and the subsequent injection of the carboxyllabeled OA-C14. Marked depression of pyrimidine nucleotide synthesis was seen at the earliest interval studied, 20 minutes. The biochemical effectiveness of 6-azauridine as an inhibitory agent was progressively lost over the following 8 hours.
DISCUSSION
In the absence of a readily detectable end-product, pyrimidine metabolism in the intact organism has been studied by a variety of other approaches. Trace amounts of pyrimidine bases may be found in urine, most evident in patients with leukemia (4) . This fraction is quantitatively much less important than that degraded through well defined pathways involving reduction to the corresponding dihydropyrimidine, hydrolysis of the ring, decarbamylation, and oxidative metabolism of the resulting ,-amino acid (7, 8) . fl-Aminoisobutyric acid, measured in urine, has been demonstrated to be derived at least in part from thymine degradation (7) . The reliability of the presence of this metabolite as an index of pyrimidine degradation is reduced by the marked variability of its urinary excretion (1) and the demonstration that it may also be formed from valine (37) .
Studies have been carried out on DNXA synthesis inf vivo, utilizing the incorporation of tritiated thymidine into hemic cells (2) , and on the utilization of pyrimidine precursors by intact human leukocytes (38) . Five sequential enzymes involved in the synthesis of UMP from carbamxl phosphate and aspartic acid have been assayed in human leukocytes and erythrocytes (5, 39) . None of these methods allows a quantitative approach to the biosynthesis of pyrimidine nucleotides in the intact organism.
The conversion of 05P to UMIP (enzyme 5, Figure 1 ) is effected by a specific irreversible decarboxylation in the only known pathway for the de novo synthesis of pyrimidine nucleotides (6 Experimental use of carboxyl-labeled 05P-C'4 in vivo is not feasible, because of the limited penetration of phosphorylated compounds across the cell membrane. Carboxyl-labeled orotidine-C14 cannot be used as a precursor of carboxyl-labeled 05P-C14 because it is not enzymatically phosphorylated (9) . In contrast, it is possible to use pyrimidine precursors with isotopic labeling of the carbon atom destined to become the carboxyl carbon of 05P. Not only are such precursors capable of crossing the cell membrane, but studies of their conversion to UMP and C140, via carboxyllabeled G5P-C14 may serve to integrate the activities of several enzymes in the pyrimidine biosynthetic pathway. In the present report, evidence has been presented to support the validity and specificity of this assay. In vivo administration of the labeled precursors has demonstrated that: 1) the release of C140G is much more rapid (6 to 10 times) after the injection of carboxyl-labeled OA-C14 or 1-carboxyl-labeled CAA-C14 than after injection of precursors labeled elsewhere in the molecule; 2) three antineoplastic agents, which have been shown in vitro to inhibit pyrimidine nucleotide formation, markedly inhibited the release of C140. from carboxyl-labeled OA-C14 and l-carboxvl-labeled CAA-C14; 3) antimetabolites active in the purine nucleotide synthetic sequence failed to exhibit such an inhibition. This evidence has been more fully discussed under Results.
Using C-6-labeled OA-C14, Hurlbert and Potter recovered 43 per cent of the isotope as pyrimidine nucleotides in rats sacrificed 2 hours after injection, with UMP achieving the highest initial specific activity (40) . Similar doses of carboxyllabeled OA-C14 administered to four rats in this laboratory resulted in the recovery of 49 per cent of the administered label in the expired air as C140G within 2 hours. Urinary losses were identical in both sets of experiments, and in each instance the liver was shown to be the major site of metabolism. The correspondence of these data further supports the reliability of measurement of expired C1409 from carboxyl-labeled pyrimidine precursors as a direct reflection of pyrimidine nucleotide biosynthesis.
There are a number of limitations inherent in the assay system employed. The difficulties involved in deriving quantitative data from the use of such distal isotopic precursors in complex biological systems may include the effect of renal excretion on the blood level of administered precursor; the transport of the precursor across the cell membrane; its distribution within intracellular compartments; the enzyme content of cells; availability of cofactors; the size, homogeneity and turnover rates of intra-and extracellular pools as well as other factors which control the appropriate activity of this biosynthetic chain of reactions.
The effect of certain of these variables on the assay system has been examined. Studies in nephrectomized rats have shown that reduction of renal excretion has no effect on the initial rate of C'4G, recovery (Table II) . The linear response of C1402 evolution to increasing doses of carboxyl-labeled OA-C14 ( Figure 9 ) suggests that neither transport mechanisms into the cell, nor enzymatic capabilities within the cell were exceeded under the experimental conditions. Data have been presented which suggest that the availability of PRPP is not a limiting condition for OA metabolism in the test as employed. No information is available concerning the size of the body pool, or, more likely, heterogeneous body pools, of orotic acid or carbamylaspartic acid into which the isotopic test compound is distributed. The pool sizes and turnover rates of the compounds subsequently formed are also unknown. None of these compounds has been detected in plasma, so that it has been impossible to approximate pool sizes in vivo. A final important variant is the size and turnover rate of the total body bicarbonate pool, which intervenes between the enzymatic release of C140, and its subsequent appearance in the expired air.
In the absence of such information, the release of C140, from carboxyl-labeled OA-C14 or 1-carboxyl-labeled CAA-C14 cannot be expressed in absolute terms of UMP synthesized. The isotopic precursor serves merely to label the 05P pool of unknown size, such that measurement of its metabolism to C140, is a reflection of UMP synthesis at that particular time in the intact organism. In addition to the de novo synthesis being studied here, it has also been demonstrated that pyrimidine nucleotides can be synthesized through reutilization of preformed pyrimidine bases (41) . No information is available on the quantitative significance of this salvage synthesis under physiological conditions.
All of these variables may reduce the absolute quantitative significance of the assay system, but do not necessarily diminish its ability to document the direction, degree, and time sequence of certain changes in pyrimidine precursor metabolism within a given test subject. In practice, the respiratory excretion of C1402 after administration of carboxyl-labeled OA-C14 was reproducible in the individual rat and showed little variation among control rats (Table I) or among the few normal subjects studied (Table III) . As an index, rather than as an absolute measurement of rate, the usefulness of this assay lies in reflecting changes in rates of de novo pyrimidine nucleotide synthesis within a given subject.
Most of the antineoplastic agents in current use have been developed as potential inhibitors of some phase of nucleic acid metabolism. Synthesized as analogues of known intermediates or cofactors in nucleic acid biosynthesis, their sites of action at an enzymatic level have often been determined with precision. The rational use of a chemotherapeutic agent is based not only on knowledge concerning its mechanism of action, but also on information concerning the rapidity of onset, degree, and duration of biochemical effectiveness. Data have been presented in this report to document the in vivo effect of 6-azauracil, 6-azauridine, 5-fluoroorotic acid, and oxonic acid on UMP synthesis as reflected in C140, release from carboxyllabeled OA-C14 or 1-carboxyl-labeled CAA-C14. Of greater importance, the assay system employed permits information to be obtained about the time sequence of change in pyrimidine metabolism after the administration of an antineoplastic agent (Figures 11, 12 ). Intraperitoneally administered 6-azauridine produced an inhibitory effect in the rat within 20 minutes (the shortest interval studied), which became maximal at 40 minutes. Thereafter, the inhibition of UMP synthesis by this antimetabolite was gradually lost over a period of 8 hours. It is of interest that previously published observations during experimental tumor chemotherapy in the mouse indicated that an 8-hour interval could not be exceeded for repeated injections of 6-azauracil (which is also converted to 6-azauridylic acid in vivo) to maintain optimal therapeutic effect (42) .
The diminution of C1402 release from carboxyllabeled primidine precursors reflects the biochentical effectiveness of antimetabolites whose sites of action are on pyrimidine biosynthesis. No information is as yet available as to whether this index accurately reflects corresponding t1herapen-tic effectiveness as antineoplastic agents.
SUM MARY 1 . Evidence has been presented that the rate of respiratory C1402 evolution from carboxyl-labeled pyrimidine precursors is an index of the synthesis in vivo of pyrimidine nucleotides.
2. The following observations support the specificity of this assay: A. The release of C140, was more rapid after the injection of carboxyl-labeled precursors than after injection of precursors labeled elsewhere in the molecule. B. Antineoplastic agents which have been shown in vitro to inhibit pyrimidine nucleotide formation markedly inhibited the release of C1409 from carboxyl-labeled precursors. C. Antimetabolites active in the purine nucleotide synthetic sequence failed to exhibit such an inhibition.
3. The method has allowed information to be obtained concerning the rapidity in onset of action, the degree of inhibition attained, and the duration of biochemical effectiveness in vivo of certain antimetabolites which inhibit pyrimidine nucleotide biosynthesis.
